Harvest Fund Management Co. Ltd bought a new stake in Amedisys Inc (NASDAQ:AMED) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 5,821 shares of the health services provider’s stock, valued at approximately $727,000.
A number of other institutional investors also recently bought and sold shares of the stock. Itau Unibanco Holding S.A. acquired a new position in shares of Amedisys in the second quarter worth $149,000. Moneta Group Investment Advisors LLC acquired a new position in shares of Amedisys in the second quarter worth $181,000. Cubist Systematic Strategies LLC grew its stake in shares of Amedisys by 1,086.0% in the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after acquiring an additional 2,172 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new position in shares of Amedisys in the third quarter worth $203,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of Amedisys in the second quarter worth $217,000. Hedge funds and other institutional investors own 93.19% of the company’s stock.
Several equities analysts have commented on AMED shares. Royal Bank of Canada boosted their price target on shares of Amedisys to $115.00 and gave the stock an “outperform” rating in a research note on Friday, August 3rd. SunTrust Banks boosted their price target on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Cantor Fitzgerald started coverage on shares of Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price target for the company. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. Finally, Robert W. Baird boosted their price target on shares of Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, October 11th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $102.38.
Amedisys stock opened at $115.18 on Wednesday. The firm has a market cap of $3.13 billion, a PE ratio of 30.57, a PEG ratio of 1.54 and a beta of 1.00. Amedisys Inc has a 12-month low of $45.60 and a 12-month high of $127.38. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.18. The business had revenue of $417.34 million during the quarter, compared to analysts’ expectations of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 22.72%. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 EPS. As a group, sell-side analysts forecast that Amedisys Inc will post 3.39 earnings per share for the current year.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.